|SOUTH ASIAN GUIDELINES FOR MANAGEMENT OF ENDOCRINE DISORDERS IN RAMADAN
|Year : 2012 | Volume
| Issue : 4 | Page : 522-524
Thyroid diseases and Ramadan
Syed A Raza1, Osama Ishtiaq2, AG Unnikrishnan3, AK Azad Khan4, Jamal Ahmad5, Mohammed A Ganie6, Kishwar Azad7, Manash Baruah8, Md Faruque Pathan7
1 Shaukhat Khanum Cancer Hospital and Research Center, Lahore, Pakistan
2 Shifa International Hospital, Islamabad, Pakistan
3 Department of Endocrinology, AIMS, Kochi, India
4 President, Diabetic Association of Bangladesh, Bangladesh
5 Rajiv Gandhi Centre for Diabetes and Endocrinology, J. N. Medical College, Aligarh Muslim University, Aligarh, India
6 Department of Endocrinology, AIIMS, New Delhi, India
7 BIRDEM and Ibrahim Medical College, Dhaka, Bangladesh
8 Department of Endocrinology, Excel Hospitals, Guwahati, India
|Date of Web Publication||5-Jul-2012|
Syed A Raza
Shaukhat Khanum Cancer Hospital and Research Center, Lahore
Source of Support: None, Conflict of Interest: None
| Abstract|| |
In the month of Ramadan, patients with thyroid diseases, most of the time, do not need treatment adjustments and can fast safely without any health hazards. Patients with hypothyroidism taking thyroxine can take their tablets on an empty stomach at bedtime instead of half an hour before Sehr. Patients with hyperthyroidism, on methimazole/carbimazole can continue their dose in once or twice daily regimes, while those on propylthiouracil need to be switched. Hyperthyroid patients with severe symptoms should start treatment immediately and can avoid fast for few days after a consultation with their religious scholar.
Keywords: Hyperthyroidism, hypothyroidism, Ramadan, thyroid disease
|How to cite this article:|
Raza SA, Ishtiaq O, Unnikrishnan A G, Azad Khan A K, Ahmad J, Ganie MA, Azad K, Baruah M, Pathan M. Thyroid diseases and Ramadan. Indian J Endocr Metab 2012;16:522-4
|How to cite this URL:|
Raza SA, Ishtiaq O, Unnikrishnan A G, Azad Khan A K, Ahmad J, Ganie MA, Azad K, Baruah M, Pathan M. Thyroid diseases and Ramadan. Indian J Endocr Metab [serial online] 2012 [cited 2019 Apr 22];16:522-4. Available from: http://www.ijem.in/text.asp?2012/16/4/522/98001
| Introduction|| |
During the month of Ramadan, Muslims from all over the world abstain from food and fluid intake from dawn (Sehr) to sunset (Iftar) for 1 month. This prolonged fasting causes several minor metabolic and hormonal changes in the body.  which rarely cause any problem to a healthy individual. However, problems do arise in certain chronic diseases like diabetes mellitus, and thus, patients are advised to consult their physicians before planning to fast. In patients with thyroid diseases, so far there are minimal data suggesting any adjustment in the treatment during Ramadan. We have explored the available evidence and provide some guidelines in this regard.
| Hypothyroidism|| |
In Ramadan, minimal changes are observed in the levels of T3, T4, and TSH in a normal person.  Few studies have shown that T4 decreases significantly during fasting in Ramadan in both genders, while TSH increases significantly in male subjects, although TSH and T4 levels stay within the normal ranges. There is a positive correlation between T4 changes and number of days of fasting in women. Most of these changes revert back to pre-Ramadan levels once fasting is over. ,
Options for thyroid hormone replacement and factors effecting absorption
Whether primary or secondary, thyroxine and its levo-isomer (levothyroxine) are the most widely available option for thyroid replacement. Thyroxine is taken usually orally (empty stomach) as recommended, as food/medications (cholestyramine resin, sucralphate, iron sulphate, calcium preparations, aluminum antacids, raloxifene, activated charcoal, various soya products, and food and herbal remedies) affect its absorption. ,,, Also a fiber-enriched diet, the traditional South Asian diet, and coffee in early morning may also interfere with the absorption of levothyroxine. , The amount absorbed decreases from 80% in the fasting state to 60% in the fed state.  So, when taken with food, the absorption of levothyroxine is incomplete, resulting in variable and higher TSH levels. Standard drug information resources recommend that levothyroxine should be taken half an hour before breakfast on an empty stomach, to prevent interference of its intestinal uptake by food or medication.  While taking thyroxine in between/with food might not be best, due to variable reasons,  taking it at bedtime is another option, as it has shown to have almost the same effect as when taken on an empty stomach. ,
| Optimal Timing for the Ingestion of Thyroid Medication During Ramadan|| |
During the month of Ramadan, changes in gastric motility (due to prolonged fasting), interference with heavy meals, possible alteration in the circadian rhythm and the effect of the deiodinase activity might alter the metabolism of the drug in the body. Based on the above information, it can be postulated that during Ramadan, the proper administration of thyroxine/levothyroxine is achieved if it is taken half an hour before Sehr. But most of the patients find it difficult to wake up that early and either miss the dose or take it with the meal. This problem can be easily managed, if levothyroxine is taken at bedtime, which too has an almost identical lowering effect (if not better) on TSH. The effect may be due to the better effect of factors such as gastric motility, heavy meals, circadian rhythms, and effect of deiodinase activity. ,,,
| Optimal Timing for Ingestion of Thyroid Medication after Ramadan|| |
As people revert back to their usual routine/habits after Ramadan, it seems more logical to go back to their routine (as before Ramadan) after the Ramadan comes to an end. Based on our current knowledge of thyroid replacement regimens, it should not have any impact on the metabolic state of the individual.
There are essentially no data on the outcome of hyperthyroid patients during Ramadan. Warning signs in a newly diagnosed or untreated thyrotoxic patient include the development of polydipsia, dehydration, diarrhea, and tachycardia, which would further worsen in the case of prolonged fasting. Patients with mild symptoms of thyrotoxicosis usually have no trouble in fasting but, those with severe symptoms can land into troublesome dehydration and diarrhea. These patients can skip fasting for few days till their symptoms improve. Quran (the holy book of Muslims) has given clear exemption to the sick people from the fast during illness but they need to compensate for the missed days of Ramadan later. Patients can also be advised to discuss with a local religious scholar for such issues.
Early diagnosis and treatment of thyrotoxicosis is deemed an emergency. The use of thionamides like methimazole, carbimazole, and propylthiouracil (PTU) is effective in patients with hyperthyroidism. They are actively transported into the thyroid gland where they inhibit both the organification of iodine to tyrosine residues in thyroglobulin and the coupling of iodotyrosines.
| Investigations and Treatment of Thyrotoxicosis During the Ramadan|| |
Thyrotoxicosis includes hyperthyroidism (excessive hormone production by thyroid) as well as thyroiditis (inflammation of the thyroid gland). These two can be easily differentiated by a thyroid uptake study/thyroid scan. Approximately 5%-10% cases of thyrotoxicosis are due to thyroiditis. Differentiation is important as the treatment of these conditions could be entirely different. The mainstay of treatment for patients suffering from thyroiditis remains NSAIDs, steroids, or beta-blockers, and it remains a self-limiting condition. The management of this disorder during Ramadan depends on the severity of symptoms.
In the treatment of hyperthyroidism, thionamides are the used. Among thionamides, propylthiouracil has a limitation during Ramdan due to its required dosing of every 4-6 h. The other most commonly used antithyroid drug "methimazole" has a fairly long duration of action, and can be taken at any time of the day in a single or divided doses.  For that reason, in Ramadan, no treatment adjustment is needed in these patients and they can be monitored on the standard protocols. The carbimazole dose required to yield an equivalent dose of methimazole is approximately 40% higher. For example, a 10 or 20 mg dose of carbimazole yields roughly 6 and 15 mg of methimazole, respectively. This drug takes a week to show its maximum effect and thus it is added with beta-blockers for quick symptomatic control. Patients prefer to stay home and avoid frequent treatment adjustments. They can be followed easily after Ramadan. If the treating physician is considering alternate treatment options like radio-active iodine or surgery, these can be delayed till the completion of Ramadan for the said reasons.
| Conclusion|| |
Although there are essentially no data on the adjustment of treatment protocols of patients with thyroid diseases, we have proposed that hypothyroid patients can take their thyroxine at bedtime easily instead of half an hour before Sehr. For hyperthyroid patients, the preferred oral antithyroid treatment is methimazole, which can be taken once or twice daily in Ramadan easily. Patients with mild to moderate symptoms of hyperthyroidism can fast safely.
| References|| |
|1.||Ziaee V, Razaei M, Ahmadinejad Z, Shaikh H, Yousefi R, Yarmohammadi L, et al. The changes of metabolic profile and weight during Ramadan fasting. Singapore Med J 2006;47:409-14. |
|2.||Mansi K, Masalmeh A. Impact of ramadan fasting on metabolism and on serum levels of some hormones among healthy Jordanian students. J Med Sci 2007;7:755-61. |
|3.||Ahmadinejad Z, Ziaee V, Rezaee M, Yarmohammadi L, Shaikh H, Bozorgi F, et al. The effect of ramadan fasting on thyroid hormone profile: A cohort study. Pak J Biol Sci 2006;9:1999-2002. |
|4.||Sajid KM, Akhtar M, Malik GQ. Ramadan fasting and thyroid hormone profile. J Pak Med Assoc 1991;41:213-6. |
|5.||Sherman SI, Tielens ET, Ladenson PW. Sucralfate causes malabsorption of L-thyroxine. Am J Med 1994;96:531-5. |
|6.||Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA 2000;283:2822-5. |
|7.||Campbell NR, Hasinoff BB, Stalts H, Rao B, Wong NC. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med 1992;117:1010-3. |
|8.||Siraj ES, Gupta MK, Reddy SS. Raloxifene causing malabsorption of levothyroxine. Arch Intern Med 2003;163:1367-70. |
|9.||Liel Y, Harman-Boehm I, Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypo- thyroid patients. J Clin Endocrinol Metab 1996;81:857-7. |
|10.||Benvenga S, Bartolone L, Pappalardo MA, Russo A, Lapa D, Giorgianni G, et al. Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid 2008;18:293-301. |
|11.||Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism, and bioavailability of Levothyroxine in the treatment of hypothyroidism. N Engl J Med 1987;316:764-70. |
|12.||Bach-Huynh TG, Nayak B, Loh J, Soldin S, Jonklaas J. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab 2009;94:3905-12. |
|13.||Huynh TG, Nayak B, Loh J, Soldin S, Jonklaas J. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin Endocrinol Metab 2009;94:3905-12. |
|14.||Bolk N, Visser TJ, Kalsbeek A, van Domburg RT, Berghout A. Effects of evening vs morning thyroxine ingestion on serum thyroid hormone profiles in hypothyroid patients. Clin Endocrinol (Oxf) 2007;66:43-8. |
|15.||Rajput R, Chatterjee S, Rajput M. Can levothyroxine be taken as evening dose? Comparative evaluation of morning versus evening dose of levothyroxine in treatment of hypothyroidism. J Thyroid Res 2011;2011:505239. |
|16.||Wilson P, Perdikis G, Hinder RA, Redmond EJ, Anselmino M, Quigley EM. Prolonged ambulatory antroduodenal manometry in humans. Am J Gastroenterol 1994;89:1489-95. |
|17.||Hays MT. Localization of human thyroxine absorption. Thyroid 1991;1:241-8. |
|18.||Stone E, Leiter LA, Lambert JR, Silverberg JD, Jeejeebhoy KN, Burrow GN. L-thyroxin absorption in patients with short bowel. J Clin Endocrinol Metab 1984;59:139-41. |
|19.||Keck ES, Wolf CF, Pfeiffer EF. The influence of circulating thyroxine serum concentration on hepatic thyroxine deiodinating activity in rats. Exp Clin Endocrinol 1990;96:269-77. |
|20.||Okamura Y, Shigemasa C, Tatsuhara T. Pharmacokinetics of methimazole in normal subjects and hyperthyroid patients. Endocrinol Jpn 1986;33:605-15. |